A randomised, double-blind, placebo-controlled trial: Intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.76, 2013, Pages

  Takehara, Kazuhiko ^a   Ihn, Hironobu ^b   Sato, Shinichi ^c  

^a KANAZAWA UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

DBT; IVIG; Systemic sclerosis

Indexed keywords

IMMUNOGLOBULIN; PLACEBO;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FEVER; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MODIFIED RODNAN SKIN THICKNESS SCORE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SCLERODERMA; SIDE EFFECT; SKIN EXAMINATION; AGED; CONTROLLED CLINICAL TRIAL; DIFFUSE SCLERODERMA; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; RETREATMENT; SKIN; TREATMENT OUTCOME;

ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PLACEBOS; RETREATMENT; SCLERODERMA, DIFFUSE; SKIN; TREATMENT OUTCOME;

EID: 84883794316     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. SHERO JH, BORDWELL B, ROTHFIELD NF, EARNSHAW WC: High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients. Science 1986; 231: 737-40.
2. MOROI Y, PEEBLES C, FRITZLER MJ, STEIGERWALD J, TAN EM: Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci USA 1980; 77: 1627-31.
3. CHUNG L, DENTON CP, DISTLER O et al.: Clinical trial design in scleroderma: where are we and where do we go next?. Clin Exp Rheumatol 2012; 30 (Suppl. 71): S97-102.
4. CLEMENTS PJ, FURST DE, WONG WK et al.: High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999; 42: 1194-203.
5. POPE JE, BELLAMY N, SEIBOLD JR et al.: A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44: 1351-8.
6. SEIBOLD JR, KORN JH, SIMMS R et al.: Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000; 132: 871-9.
7. SEIBOLD JR, CLEMENTS PJ, KORN JH et al.: Phase III trial of relaxin in diffuse scleroderma. J Rheumatol 2001; 28 (S63): 55.
8. BRANDT D, GERSHWIN ME: Common variable immune deficiency and autoimmunity. Autoimmun Rev 2006; 5: 465-70.
9. YAMAMOTO T, KURODA M, NISHIOKA K: Animal model of sclerotic skin. III: histopathological comparison of bleomycin-induced scleroderma in various mice strains. Arch Dermatol Res 2000; 292: 535-41.
10. LEVY Y, SHERER Y, LANGEVITZ P et al.: Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin-- a preliminary report. Clin Rheumatol 2000; 19: 207-11.
11. LEVY Y, AMITAL H, LANGEVITZ P et al.: Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. Arthritis Rheum 2004; 50: 1005-7.
12. NACCI F, RIGHI A, CONFORTI ML et al.: Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study. Ann Rheum Dis 2007; 66: 977-9.
13. IHN H, MIMURA Y, YAZAWA N et al.: Highdose immunoglobulin infusion as treatment for diffuse scleroderma. Br J Dermatol 2007; 156: 1058-60.
14. ASANO Y, IHN H, ASASHIMA N et al.: A case of diffuse scleroderma successfully treated with high-dose intravenous immunoglobulin infusion. Rheumatology (Oxford) 2005; 44: 824-6.
15. BLANK M, LEVY Y, AMITAL H, SHOENFELD Y: The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice. Arthritis Rheum 2002; 46: 1689- 90.
16. KAJII M, SUZUKI C, KASHIHARA J et al.: Prevention of excessive collagen accumulation by human intravenous immunoglobulin treatment in a murine model of bleomycininduced scleroderma. Clin Exp Immunol 2011; 163: 235-41.